Add time:08/18/2019 Source:sciencedirect.com
A systematic review identified 86 outcome–based clinical trials involving perindopril, amlodipine, or other antihypertensive drugs. In fixed–effects meta–analyses of 11 clinical trials (90,208 subjects), amlodipine was associated with a significant 24% increase in heart failure, but a significant decrease in death, cardiovascular death, stroke, coronary heart disease, and first major cardiovascular adverse event. In five clinical trials (52,565 subjects), perindopril was associated with a significant reduction in all six cardiovascular endpoints. Network and Bayesian meta–analyses suggested that (with the exception of amlodipine and heart failure), each agent was at least as effective as an initial diuretic to prevent these events. Short–term trials have demonstrated that the combination of perindopril and amlodipine is safe and effective, with statistically greater lowering of blood pressure than either agent alone and a potential synergistic effect on pedal edema. The single–pill combination of perindopril and amlodipine may be a useful addition to the antihypertensive armamentarium.
We also recommend Trading Suppliers and Manufacturers of Perindopril erbumine (cas 107133-36-8). Pls Click Website Link as below: cas 107133-36-8 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View